Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins

– First collaboration program, leveraging Cyrus’ de novo computational approach to create proprietary IL-2 protein agonist targeting autoimmune and other deleterious immune conditions-

-Preclinical data demonstrate synergistic activity of ImmTOR in combination with IL-2 mutein to increase the level and durability of Treg expansion-

– Unlocking a new generation of innovative biologic therapeutics with the potential to improve the lives of patients-

WATERTOWN, Mass. and SEATTLE, Sept. 08, 2021 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Cyrus Biotechnology, Inc. a leading protein design company, today announced a protein engineering collaboration combining Selecta’s ImmTOR platform with Cyrus’ ability to radically redesign protein therapeutics. The lead program in the collaboration is a proprietary interleukin-2 (IL-2) protein agonist designed to selectively promote expansion of regulatory T cells (Treg) for the treatment of patients with autoimmune diseases and other deleterious immune conditions.

Novel IL-2 approaches and technologies are driving innovation in the therapeutic development space. The IL-2 pathway influences critical aspects of both immune stimulation and immune regulation, through the development and expansion of regulatory T cells (Treg). These Treg cells are a specialized subpopulation of T cells involved in suppressing certain immune responses and maintaining the body’s self-tolerance. Reductions in the number of Treg cells have been shown to drive a spectrum of autoimmune diseases and conversely, increasing Treg expansion may have clinical utility in reducing inflammation and improving disease outcomes. Early preclinical data investigating the effects of ImmTOR in combination with a Treg-selective IL-2 mutant protein (IL-2 “mutein”) demonstrate substantial synergistic activity in increasing the percentage and durability of Treg expansion in the spleen (Figure below). This supports the potential of ImmTOR in combination with IL-2 proteins to restore immunotolerance to autoantigens and forms the basis for this partnership. Although IL-2 has been an attractive target for autoimmune indications, overcoming its immunostimulatory activities, short half-life and anti-IL-2 antibody formation has been challenging. Building on recent advancements in the field, our strong preliminary data suggest that ImmTOR in combination with Cyrus’ novel IL-2 protein agonist has the potential to unlock the value of this target and drive the development of a next generation, best-in-class asset.

A figure accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/eb50b792-d824-4b4b-8e60-c2135fe26e2e

“We are excited to collaborate with Cyrus, and we see this strategic protein engineering partnership as an important step in advancing our ImmTOR platform for the treatment of autoimmune diseases,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. “We are encouraged by the preclinical data generated to date and the growing literature that supports the potential of IL-2 therapeutics in treating immunological diseases.”

Dr. Brunn added, “We look forward to leveraging Cyrus’ ability to both reengineer immune epitopes and rationally design novel proteins using non-traditional starting sequences, including non-human, non-natural and ancestral versions. For our first program, this combination will allow us to potentially mitigate unwanted immune responses by reducing the inherent immunogenicity of the protein while also promoting immune tolerance. We are fortunate to have this opportunity to optimize and advance our portfolio through the design and generation of innovative protein therapeutics. Beyond leading a paradigm shift in the way biologics are made, ultimately this collaboration has the potential to unlock new treatment options and improve the lives of patients who suffer from serious and debilitating diseases.”

Lucas Nivon, Ph.D., Chief Executive Officer of Cyrus, commented, “We welcome Selecta as a deeply experienced partner. This collaboration is in perfect alignment with our protein design expertise and represents an important endorsement of our platform, which has the potential to further enhance the potency of ImmTOR’s tolerizing power. With our current partners, we have demonstrated our ability to redesign existing protein biologics or build them from the ground-up — expanding the potential for therapeutics and intellectual property. We look forward to executing on our shared vision.”

Under the terms of the collaboration, Selecta has provided an upfront payment, and Cyrus is eligible to earn discovery, development and sales based milestones. Novel engineered protein therapeutic candidates from the partnership will be used to expand Selecta’s proprietary pipeline and further bolster Selecta’s clinically validated ImmTOR platform.

https://www.globenewswire.com/news-release/2021/09/08/2293345/0/en/Selecta-Biosciences-and-Cyrus-Biotechnology-Enter-Collaboration-to-Create-Novel-Engineered-Therapeutic-Proteins.html

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

About Cyrus Biotechnology
Cyrus Biotechnology is a pre-clinical-stage biotechnology company applying leading computational protein design capabilities coupled with massively parallel in vitro screening to engineer novel biologics drugs. Cyrus is advancing a novel pre-clinical infectious disease therapeutic and developing a pipeline of internal and partnered discovery programs over a range of indications, including next-generation CRISPR therapeutics in collaboration with the Broad Institute. Cyrus founders include Dr. David Baker of the University of Washington and the company’s platform is based on core software from the Baker lab. The company has worked with over 100 industry partners, including 13 of the top 20 global Pharma firms. Cyrus is based in Seattle, WA and financed by leading Biotech and Tech investors including Orbimed, Trinity, Springrock, WRF and Alexandria. For more information please visit cyrusbio.com.

Contacts
Cyrus Biotechnology, Inc.
Lucas Nivon, 206-258-6561
lucas@cyrusbio.com

Scientific Summary: Cyrus NextGen Antibody structure prediction beats Schrodinger and others in a large independent benchmark

Over the last few years Cyrus has worked on problems on a range of proteins from enzymes to non-antibody biologics to vaccines to some antibody work. However most biologic drugs are monoclonal antibodies or variants thereof, and historically this has been a small share of our work, and an area where there are many very strong commercial offerings. Our antibody structure prediction tool, based on previous methods in Rosetta, has been a good competitor in that space, but has faced stiff competition. 

In other areas of protein structure prediction using structural homology, Rosetta and Cyrus have been the leaders in many independent benchmarks by academics and in blind tests by industry users. In antibody structure that has not been the case, given very good algorithms from Schrodinger and CCG. 

Over the last two years scientists at Cyrus, led by our CSO Dr. Yifan Song, have built a new method for antibody prediction based on Rosetta algorithms historically used for general protein homology, but not for antibodies — Cyrus NextGen Antibody. Because these algorithms have performed so well over the last 7 years since their introduction in 2013 for general protein structure prediction, many of us expected that they would perform well for antibodies once properly adapted and tuned. 

In the fall of 2019 we completed this work, and our internal testing showed clear superiority, producing more accurate structures than any other method. The gold standard, though, would be a test by a third party, judged by their own quantitative criteria, across a relatively large number of antibodies. 

Now, in July 2020, we’ve completed such a test over 26 antibodies with NextGen against the latest Schrodinger software and two other top-performing software packages. We were very pleased to find that NextGen outperformed all of the other methods in this rigorous test, and now we are publicizing these results for the first time in a scientific blog post, before making a more extensive manuscript available. 

This is an important step forward for Cyrus, but more importantly it promises more accurate results in antibody efficacy and safety predictions, and ultimately a variety of better and more effective antibody drugs produced by Cyrus algorithms for a wide range of diseases. For example, better models from NextGen could enable faster development of an antibody drug, or make certain diseases susceptible to antibody drugs for the first time. Better models could also enable the invention of second-generation versions of existing drugs, such as the popular “TNF-alpha inhibitor” arthritis drugs, with fewer immunogenic side effects or less frequent injections. 

Read Benchmark Details


New Cyrus “NextGen” antibody software outperforms the competition in third party test with BIOCAD biotechnology

Summary

Cyrus has developed a “NextGen” antibody structure prediction tool (NextGen) based on the RosettaCM “hybridize” algorithm (1). Cyrus customized and modified RosettaCM for antibody structures with an antibody-specific database, sequence parsing, and by taking antibody-specific heavy-light chain orientation into account. 

NextGen was developed and benchmarked on the test set of antibody structures from the AMA-II (2). In those tests, the NextGen tool produced more accurate models (measured by RMSD metrics) for the AMA-II antibodies, compared with all other entrants in AMA-II, including Schrödinger, CCG and older Rosetta algorithms. 

To independently validate these results we worked with BIOCAD (https://biocadglobal.com) on a 26-protein test set to compare Cyrus NextGen antibody structure prediction with Schrödinger and  another major vendor software. Tests were performed as follows:

  • BIOCAD scientists ran predictions using all non-Cyrus software
  • Cyrus scientists produced models by running NextGen
  • BIOCAD scientists calculated the metrics described below on the models produced by Cyrus and other software

Cyrus NextGen was the most accurate antibody modeling tool across all of the tested methods in this independent test (Figure 1). 

A sample structure overlay of a crystal structure and a NextGen antibody model is shown in Figure 2

Cyrus is releasing these results here directly for rapid dissemination and will release a more detailed white paper describing the methods and results once that manuscript is ready.

A screenshot of a cell phoneDescription automatically generated

Figure 1. Antibody model accuracy over the BIOCAD set of 26 antibody-Fv structures using the sum of metrics described here in “BIOCAD structure similarity metrics” — lower is more accurate. 

Figure 2. Example structure prediction using NextGen antibody, with Cyan = Crystal Structure. Light Brown = NextGen predicted structure (PDB 4M61)

BIOCAD Dataset

The BIOCAD antibody data set consists of 26 recently-released structures of bound and unbound antibody structures (Fv domains consisting of heavy (VH) and light (VL) chains), which Cyrus did not use as templates for NextGen structure prediction. 

BIOCAD structure similarity metrics

BIOCAD calculated the structural variation of predicted models for each VH-VL antibody complex in comparison to the crystal structures in order to compare model quality of the top-performing algorithms. Combined, there are 50 parameters for each structure which fall into 10 categories.

  1. RMSD of all Ca per chain when aligned by chain

The first type of metric calculates the Root Mean Square Deviation (RMSD) between alpha Carbons (Ca) of the experimental and predicted structures when aligned by chain. (2 parameters per structure).

  1. RMSD of CDR N-Ca-C when aligned by chain

The second metric calculates the RMSD between the backbone atoms (Nitrogen, Ca, and Carbonyl Carbon aka N-Ca-C) in the CDR residues of the experimental and predicted structures when aligned by chain. (6 parameters per structure).

  1. RMSD of CDR Heavy Atoms when aligned by chain

The third metric calculates the RMSD between the Heavy Atoms CDR residues of the experimental and predicted structures when aligned by chain. (6 parameters per structure).

  1. RMSD of CDR N-Ca-C when aligned by CDR

This metric calculates the RMSD between the Na-Ca-C in the CDR residues of the experimental and predicted structures when aligned by each CDR. (6 parameters per structure)

  1. RMSD of CDR Heavy Atoms when aligned by CDR

The third metric calculates the RMSD between the Heavy Atoms in the CDR residues of the experimental and predicted structures when aligned by each CDR. (6 parameters per structure).

  1. Difference between the Stem Length for each loop

For each loop, the distance is calculated between the Ca of the two Framework (Fr) residues before and after the loop. (6 parameters per structure).

  1. Alpha and Tau Angles per CDR

For each loop, the Alpha Angle is calculated by measuring the flat angle created by the last 3 Ca in the CDR. The Tau Angle is calculated by measuring the dihedral angle created by the last 3 Ca in the CDR and the next Fr Ca. (12 parameters per structure).

  1. Distance between the pivot for VH and VL

Four non-atomic positions are defined by Marze et al (3) which characterize the orientation between the Heavy and Light chains. Positions 2 and 3 are the pivot points for the Heavy and Light chains. This distance is calculated once for the structure (c in figure 3). (1 parameter per structure).

  1. Two flat and one dihedral Angle for the Marze positions

For the four positions defined by Marze et al, there are two flat angles between positions 1, 2, and 3 and between positions 2, 3, and 4 and the dihedral for all 4 positions. These were calculated once per structure (a, d, and e in Figure 3). (3 parameters per structure).

Figure 3. From Marze et al (3), a) orientation between the heavy and light chain is calculated by establishing 4 positions at conserved spots with respect to 4 framework sheets. b) The Packing angle, c) Interdomain distance, d) light Opening Angle, and the heavy Opening Angle are calculated as shown based on these 4 points.

  1.  Principal Component Analysis (PCA) Angles

Dunbar et al (4) described a PCA protocol for calculating the orientation between Heavy and Light chains. Two of those flat angles, Tilt and Twist, are calculated following that method. (2 parameters per structure). 

Scoring and Ranking

Starting from these 50 parameters, BIOCAD ran PCA to determine the correlation among parameters. They found that 99% of the variance can be retained without 34 of the 50 parameters. As a result, BIOCAD defined 16 parameters and calculated a linear combination of the original 50 parameters. The weights for the linear combinations are the first 16 eigenvectors of the covariance matrix. 

The resulting difference score is the euclidean norm of the final 16 components. If the compared structures are the same, the sum is equal to zero. The more the structures differ, the larger the sum becomes. A perfect prediction algorithm would score 0 in this sum metric, but of course even crystal structures of the same protein under different conditions differ slightly, so a 0 score is not possible.

Scores are then used to rank each antibody from each group/algorithm/method. The sum of the ranks provides an overall performance ranking per group of all 26 antibodies in the BIOCAD dataset. A lower overall summed score indicates better predictive performance for each group/algorithm.

References

  1. High-Resolution Comparative Modeling with RosettaCM. Song Y, DiMaio F, Yu-Ruei Wang R, Kim D, Miles C, Brunette TJ, Thompson J, Baker D. Structure. 2013 Oct;21(10):1735-1742
    https://www.sciencedirect.com/science/article/pii/S0969212613002979
  1. Second Antibody Modeling Assessment (AMA-II). Almagro JC, Teplyakov A, J Luo, RW Sweet, S Kodangattil, F Hernandez-Guzman, G. Gilliland. Proteins. 2014 Aug;82(8): 1552-1562. 
    https://onlinelibrary.wiley.com/doi/abs/10.1002/prot.24567
  1. Improved prediction of antibody VL-VH orientation. Marze NA, Lyskov S, Gray JJ. Protein Eng Des Sel. 2016 Oct;29(10):409-418.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036862/
  2. ABangle: characterising the VH-VL orientation in antibodies. Dunbar J, Fuchs A, Shi J, Deane CM. Protein Eng Des Sel. 2013 Oct;26(10):611-20.
    https://academic.oup.com/peds/article/26/10/611/1509255

Attachments

2020.07.16.-Cyrus-Antibody-Nextgen-BIOCAD.pdf

Use of Cyrus Bench cited in review article of human diseases caused by formin INF2 mutations

SEATTLE, WA July 13, 2020 — Cyrus Bench®, Cyrus Biotechnology, Inc.’s SaaS platform for protein engineering, has been used in a recent review article in Cellular and Molecular Life Sciences to correlate computationally predicted alterations in protein stability due to mutation with disease severity (Labat-de-Hoz L, et al. Cell Mol Life Sci. 2020).

The formin INF2 protein has emerged as an important target of mutations responsible for the appearance of focal segmental glomerulosclerosis (FSGS), which often leads to end-stage renal disease (ESRD), and for the concurrence of FSGS with Charcot–Marie–Tooth disease (CMT), a degenerative neurological disorder affecting peripheral nerves.

As part of a systematic and comprehensive analysis of the pathogenic INF2 missense mutations in patients, Cyrus Bench® ΔΔG was used to predict the impact on protein stability and structure of 54 mutations relative to the structure of the wild-type protein. 

The mutations causing FSGS + CMT were generally predicted to have a more destabilizing effect than those producing only FSGS. This is consistent with the fact that FSGS + CMT mutations are more harmful than those producing isolated FSGS, because they produce earlier ESRD.

About Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a privately-held Seattle-based biotechnology software company offering software and partnerships for protein engineering to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus methods are based on the Rosetta software from Prof. David Baker’s laboratory at the University of Washington and HHMI, the most powerful protein engineering software available. Cyrus customers include 13 of the top 20 Global Pharmaceutical firms and is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund.

https://cyrusbio.com

Contacts
Cyrus Biotechnology, Inc.
Lucas Nivon, 206-258-6561
lucas@cyrusbio.com

Prediction of protein mutational free energy: benchmark and sampling improvements increase classification accuracy

SEATTLE, WA March 20, 2020 — Software to predict the change in protein stability upon point mutation is a valuable tool for a number of biotechnological and scientific problems. To facilitate the development of such software and provide easy access to the available experimental data, the ProTherm database was created. Biases in the methods and types of information collected has led to disparity in the types of mutations for which experimental data is available. For example, mutations to alanine are hugely overrepresented whereas those involving charged residues, especially from one charged residue to another, are underrepresented. ProTherm subsets created as benchmark sets that do not account for this often underrepresented certain mutational types. This issue introduces systematic biases into previously published protocols’ ability to accurately predict the change in folding energy on these classes of mutations. To resolve this issue, we have generated a new benchmark set with these problems corrected. We have then used the benchmark set to test a number of improvements to the point mutation energetics tools in the Rosetta software suite.

https://www.biorxiv.org/content/10.1101/2020.03.18.989657v1

Authors:

Brandon Frenz, Steven Lewis, Indigo King, Hahnbeom Park, Frank DiMaio, Yifan Song

About Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a privately-held Seattle-based biotechnology software company offering software and partnerships for protein engineering to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus methods are based on the Rosetta software from Prof. David Baker’s laboratory at the University of Washington and HHMI, the most powerful protein engineering software available. Cyrus customers include 13 of the top 20 Global Pharmaceutical firms and is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund.

https://cyrusbio.com

Contacts
Cyrus Biotechnology, Inc.
Lucas Nivon, 206-258-6561
lucas@cyrusbio.com

https://xconomy.com/national/2019/12/03/a-safer-crispr-cyrus-broad-institute-look-to-quell-concerns/

https://xconomy.com/national/2019/12/03/a-safer-crispr-cyrus-broad-institute-look-to-quell-concerns/

https://www.fiercebiotech.com/biotech/cyrus-broad-team-up-to-make-vivo-crispr-use-safer

https://www.fiercebiotech.com/biotech/cyrus-broad-team-up-to-make-vivo-crispr-use-safer

https://www.geekwire.com/2019/cyrus-biotechnology-teams-crispr-pioneers-boost-gene-editing-therapies/

https://www.geekwire.com/2019/cyrus-biotechnology-teams-crispr-pioneers-boost-gene-editing-therapies/

Cyrus Biotechnology and the Broad Institute of MIT and Harvard Launch Multi-Target Collaboration to Develop Optimized CRISPR Gene Editing Technology

CAMBRIDGE, Mass. & SEATTLE — Cyrus Biotechnology, Inc., and the Broad Institute of MIT and Harvard have embarked on a scientific collaboration to optimize CRISPR for use in developing novel human therapeutics.

CRISPR allows for the highly specific and rapid modification of DNA in a genome, which can dramatically accelerate the drug discovery process.

Feng Zhang will be the principal investigator for the Broad for the collaboration. He is also an investigator of the Howard Hughes Medical Institute (HHMI).

Together, researchers from Cyrus and Broad will work together to mitigate the possibility of the body mounting an immune response against CRISPR. The teams are committed to making the results of their collaboration broadly available for research to help ensure that therapeutic development — bringing this technology to the clinic — has the best chance of success, while also considering important ethical and safety concerns. The teams have also committed to publishing their results in peer reviewed journals and to make this work freely available to the non-profit and academic scientific community.

Issi Rozen, chief business officer at the Broad Institute, said, “Broad researchers and their collaborators have pioneered the development and sharing of new genome editing tools, such as CRISPR-Cas9, which are revolutionizing and accelerating nearly every aspect of disease research and drug discovery around the world. With this collaboration, scientists will continue to improve the technology towards new tools and therapeutics, important to benefiting patients in the long term.”

Cyrus CEO Dr. Lucas Nivón added, “We have validated our computational deimmunization platform in a variety of systems, and now seek to apply it where it can make a major impact. Given the extensive therapeutic possibilities of CRISPR systems, and the leading position the Broad Institute and Dr. Zhang hold, we are very excited to work in partnership with them to make these molecules more amenable for use in humans with maximal efficacy and minimal side effects.”

Cyrus provides commercial and partnered access to Rosetta, which is the world’s leading protein modeling and design software platform. Rosetta has been used to direct the computational design of multiple biologic molecules that have advanced to both pre-clinical and clinical development. Among these are drugs being developed by companies including PVP Biologics, Tocagen, Lyell and others.

https://www.businesswire.com/news/home/20191202005078/en/Cyrus-Biotechnology-Broad-Institute-MIT-Harvard-Launch

About Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a privately-held Seattle-based biotechnology software company offering software and partnerships for protein engineering to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus methods are based on the Rosetta software from Prof. David Baker’s laboratory at the University of Washington and HHMI, the most powerful protein engineering software available. Cyrus customers include 13 of the top 20 Global Pharmaceutical firms and is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund.

https://cyrusbio.com

Contacts
Cyrus Biotechnology, Inc.
Lucas Nivon, 206-258-6561
lucas@cyrusbio.com

Cyrus Biotechnology Offers CryoEM Services based on First-in-class, Peer-reviewed Rosetta Software Methods

SEATTLE, WA August 27, 2019 — Cyrus Biotechnology, Inc., a Seattle-based biotech software company specializing in the use and commercialization of Rosetta, the world’s leading computational protein design platform, announces the availability of CryoEM services to generate high precision models from CryoEM data.

“Over the last several years, CryoEM has emerged as the key new structural method across drug discovery, from small molecules to vaccines,” notes Cyrus CEO Dr. Lucas Nivon. “Our customers have been asking for the powerful and complex CryoEM structure determination and refinement capabilities of Rosetta, which we are now providing via consulting services to Cyrus customers.”

Several publications have demonstrated that Rosetta CryoEM refinement yields far better structures than those obtained from other software methods, including key results in Nature Methods and PNAS.

Rosetta offers state-of-the art refinement, model docking into density, and de novo model building for a broad range of CryoEM map resolutions. Combined with demonstrably superior homology modeling predictions, Rosetta can go from map and sequence to full atomic-level accuracy models.

Customers without the resources or expertise to use CryoEM Rosetta structure solution and refinement tools can now take advantage of Cyrus CryoEM Services, which draw from Cyrus in-house expertise from multiple co-authors of these cutting-edge Rosetta/CryoEM methods.

Cyrus CryoEM services include: structure refinement into density, model building de novo, partial model building, and model building with modifications such as carbohydrates. Cyrus partners with leading laboratories to gather CryoEM data if a customer does not have such facilities. Read more at https://cyrusbio.com/cryoem/

Cyrus CryoEM services can be offered immediately. Please contact us to request a proposal: https://cyrusbio.com/request-cryoem-services/

https://www.businesswire.com/news/home/20190827005088/en/Cyrus-Biotechnology-Offers-CryoEM-Services-Based-First-in-class

About Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a privately held biotechnology software company offering scientific consulting services and the Cyrus Bench® SaaS platform for protein engineering to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology Industries. Cyrus services are based on the Rosetta software from Prof. David Baker’s laboratory at the University of Washington. Rosetta is the most powerful protein engineering software available. Cyrus customers include 13 of the top 20 Global Pharmaceutical firms. The company is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund.

https://cyrusbio.com/

Cyrus Contact – Lucas Nivon

lucas@cyrusbio.com

206-258-6561